NSC 23766

Selective inhibitor of Rac1-GEF interaction. CAS# 1177865-17-6

NSC 23766

Catalog No. BCC1149----Order now to get a substantial discount!

Product Name & Size Price Stock
NSC 23766: 5mg $58 In Stock
NSC 23766: 10mg Please Inquire In Stock
NSC 23766: 20mg Please Inquire Please Inquire
NSC 23766: 50mg Please Inquire Please Inquire
NSC 23766: 100mg Please Inquire Please Inquire
NSC 23766: 200mg Please Inquire Please Inquire
NSC 23766: 500mg Please Inquire Please Inquire
NSC 23766: 1000mg Please Inquire Please Inquire
Related Products
  • EHop-016

    Catalog No.:BCC5022
    CAS No.:1380432-32-5
  • ZCL278

    Catalog No.:BCC3665
    CAS No.:587841-73-4
  • EHT 1864

    Catalog No.:BCC6075
    CAS No.:754240-09-0
  • AS 1892802

    Catalog No.:BCC6335
    CAS No.:928320-12-1

Quality Control of NSC 23766

Number of papers citing our products

Chemical structure

NSC 23766

3D structure

Chemical Properties of NSC 23766

Cas No. 1177865-17-6 SDF Download SDF
PubChem ID 16759159 Appearance Powder
Formula C24H38Cl3N7 M.Wt 530.96
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 33.33 mg/mL (62.77 mM; Need ultrasonic)
H2O : ≥ 32 mg/mL (60.27 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 6-N-[2-[5-(diethylamino)pentan-2-ylamino]-6-methylpyrimidin-4-yl]-2-methylquinoline-4,6-diamine;trihydrochloride
SMILES CCN(CC)CCCC(C)NC1=NC(=CC(=N1)NC2=CC3=C(C=C2)N=C(C=C3N)C)C.Cl.Cl.Cl
Standard InChIKey CPUHORIUXPQCHW-UHFFFAOYSA-N
Standard InChI InChI=1S/C24H35N7.3ClH/c1-6-31(7-2)12-8-9-16(3)27-24-28-18(5)14-23(30-24)29-19-10-11-22-20(15-19)21(25)13-17(4)26-22;;;/h10-11,13-16H,6-9,12H2,1-5H3,(H2,25,26)(H2,27,28,29,30);3*1H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of NSC 23766

DescriptionSelective inhibitor of Rac1-GEF interaction. Prevents Rac1 activation by Rac-specific guanine nucleotide exchange factors (GEFs) TrioN and Tiam1 (IC50 ~ 50 μM) without affecting Cdc42 or RhoA activation. Inhibits Rac1-mediated cell functions and is reported to reverse tumor cell phenotyes in prostate cancer cells.

NSC 23766 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

NSC 23766 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of NSC 23766

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.8834 mL 9.4169 mL 18.8338 mL 37.6676 mL 47.0845 mL
5 mM 0.3767 mL 1.8834 mL 3.7668 mL 7.5335 mL 9.4169 mL
10 mM 0.1883 mL 0.9417 mL 1.8834 mL 3.7668 mL 4.7085 mL
50 mM 0.0377 mL 0.1883 mL 0.3767 mL 0.7534 mL 0.9417 mL
100 mM 0.0188 mL 0.0942 mL 0.1883 mL 0.3767 mL 0.4708 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on NSC 23766

NSC-23766 is a specific inhibitor of Rac with IC50 of 50μM.

NSC-23766 blocks the activation of Rac 1 through binding the GEFs including Trio and Tiam 1 [1]. In human dermal microvascular endothelial cells, NSC-23766 decreased trans-endothelial electrical resistance and caused the intercellular gap formation. Inhibition of Rac 1 by NSC-23766 shortly reduced endothelial barrier functions as revealed by measurement of TER and the appearance of intracellular gaps [2]. In the mucous cell of the intestine, inhibition of Rac1 either by NSC-23766 protected cells from TNF-α-induced apoptosis by inhibiting caspase-3, -8 and -9 activities. Inhibition of Rac1 significantly prevented TNF-α-induced activation of JNK1/2, but did not modulate TNF-α-induced ERK1/2, Akt and p38 MAPK activity [3].

References:
[1]. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A. 2004 May 18;101(20):7618-23.
[2]. Baumer Y, Spindler V, Werthmann RC, Bünemann M, Waschke J. Role of Rac 1 and cAMP in endothelial barrier stabilization and thrombin-induced barrier breakdown. J Cell Physiol. 2009 Sep;220(3):716-26.
[3]. Jin S1, Ray RM, Johnson LR. Rac1 mediates intestinal epithelial cell apoptosis via JNK. Am J Physiol Gastrointest Liver Physiol. 2006 Dec;291(6):G1137-47.

Featured Products
New Products
 

References on NSC 23766

VEGF alleviates ALS-CSF induced cytoplasmic accumulations of TDP-43 and FUS/TLS in NSC-34 cells.[Pubmed:28163215]

J Chem Neuroanat. 2017 Apr;81:48-52.

Cytoplasmic mislocalisation and aggregation of TDP-43 and FUS/TLS proteins in spinal motor neurons contribute to the pathogenesis of the highly fatal disorder amyotrophic lateral sclerosis (ALS). We investigated the neuroprotective effect of VEGF on expression of these proteins in the motor neuronal cell line NSC-34 modelled to reminisce sporadic form of ALS. We studied the expression of TDP-43 and FUS/TLS proteins after exposure to ALS-CSF and following VEGF supplementation by quantitative confocal microscopy and electron microscopy. ALS-CSF caused cytoplasmic overexpression of both the proteins and stress-granule formation in the cells. These alterations were alleviated by VEGF supplementation. The related ultrastructural changes like nuclear membrane dysmorphism and p-bodies associated changes were also reversed. However the protein expression did not completely translocate to the nucleus, as some cells continued to show to cytoplasmic mislocalisation. Thus, the present findings indicate that VEGF alleviates TDP43 and FUS pathology by complimenting its role in controlling apoptosis and reversing choline acetyl transferase expression. Hence, VEGF appears to target multiple pathogenic processes in the neurodegenerative cascade of ALS.

Important modifications by sugammadex, a modified gamma-cyclodextrin, of ion currents in differentiated NSC-34 neuronal cells.[Pubmed:28049438]

BMC Neurosci. 2017 Jan 3;18(1):6.

BACKGROUND: Sugammadex (SGX) is a modified gamma-cyclodextrin used for reversal of steroidal neuromuscular blocking agents during general anesthesia. Despite its application in clinical use, whether SGX treatment exerts any effects on membrane ion currents in neurons remains largely unclear. In this study, effects of SGX treatment on ion currents, particularly on delayed-rectifier K(+) current [I K(DR)], were extensively investigated in differentiated NSC-34 neuronal cells. RESULTS: After cells were exposed to SGX (30 muM), there was a reduction in the amplitude of I K(DR) followed by an apparent slowing in current activation in response to membrane depolarization. The challenge of cells with SGX produced a depolarized shift by 15 mV in the activation curve of I K(DR) accompanied by increased gating charge of this current. However, the inactivation curve of I K(DR) remained unchanged following SGX treatment, as compared with that in untreated cells. According to a minimal reaction scheme, the lengthening of activation time constant of I K(DR) caused by cell treatment with different SGX concentrations was quantitatively estimated with a dissociation constant of 17.5 muM, a value that is clinically achievable. Accumulative slowing in I K(DR) activation elicited by repetitive stimuli was enhanced in SGX-treated cells. SGX treatment did not alter the amplitude of voltage-gated Na(+) currents. In SGX-treated cells, dexamethasone (30 muM), a synthetic glucocorticoid, produced little or no effect on L-type Ca(2+) currents, although it effectively suppressed the amplitude of this current in untreated cells. CONCLUSIONS: The treatment of SGX may influence the amplitude and gating of I K(DR) and its actions could potentially contribute to functional activities of motor neurons if similar results were found in vivo.

Adult NSC diversity and plasticity: the role of the niche.[Pubmed:27978480]

Curr Opin Neurobiol. 2017 Feb;42:68-74.

Adult somatic stem cells are generally defined as cells with the ability to differentiate into multiple different lineages and to self-renew during long periods of time. These features were long presumed to be represented in one single tissue-specific stem cell. Recent development of single-cell technologies reveals the existence of diversity in fate and activation state of somatic stem cells within the blood, skin and intestinal compartments [1] but also in the adult brain. Here we review how recent advances have expanded our view of neural stem cells (NSCs) as a diverse pool of cells and how the specialized microenvironment in which they reside acts to maintain this diversity. In addition, we discuss the plasticity of the system in the injured brain.

c-Jun Amino-Terminal Kinase is Involved in Valproic Acid-Mediated Neuronal Differentiation of Mouse Embryonic NSCs and Neurite Outgrowth of NSC-Derived Neurons.[Pubmed:28321599]

Neurochem Res. 2017 Apr;42(4):1254-1266.

Valproic acid (VPA), an anticonvulsant and mood-stabilizing drug, can induce neuronal differentiation, promote neurite extension and exert a neuroprotective effect in central nervous system (CNS) injuries; however, comparatively little is known regarding its action on mouse embryonic neural stem cells (NSCs) and the underlying molecular mechanism. Recent studies suggested that c-Jun N-terminal kinase (JNK) is required for neurite outgrowth and neuronal differentiation during neuronal development. In the present study, we cultured mouse embryonic NSCs and treated the cells with 1 mM VPA for up to 7 days. The results indicate that VPA promotes the neuronal differentiation of mouse embryonic NSCs and neurite outgrowth of NSC-derived neurons; moreover, VPA induces the phosphorylation of c-Jun by JNK. In contrast, the specific JNK inhibitor SP600125 decreased the VPA-stimulated increase in neuronal differentiation of mouse embryonic NSCs and neurite outgrowth of NSC-derived neurons. Taken together, these results suggest that VPA promotes neuronal differentiation of mouse embryonic NSCs and neurite outgrowth of NSC-derived neurons. Moreover, JNK activation is involved in the effects of VPA stimulation.

Description

NSC 23766 trihydrochloride is an inhibitor of Rac1 activation.

Keywords:

NSC 23766,1177865-17-6,Natural Products,Rho, buy NSC 23766 , NSC 23766 supplier , purchase NSC 23766 , NSC 23766 cost , NSC 23766 manufacturer , order NSC 23766 , high purity NSC 23766

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: